Comprehensive Metabolic Profiling of Resigratinib, a Novel FGFR Inhibitor, Using Integrated LC–MS/MS and LC‐Orbitrap‐HRMS
Rapid Communications in Mass Spectrometry · 2025
DOI: 10.1002/rcm.10141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rapid Communications in Mass Spectrometry, 2025. Verfasst von Xiaoxia An und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Receptors, Fibroblast Growth Factor. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Rationale
Resigratinib, a potent fibroblast growth factor receptor (FGFR) inhibitor, is under clinical development for solid tumors such as cholangiocarcinoma. However, data on its hepatic metabolism remain limited. To support further development, this study aimed to characterize its in vitro metabolism using rat, dog, monkey, and human liver microsomes.
Methods
A sensitive and robust liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was validated for quantifying resigratinib in liver microsomes. Metabolite characterization was performed using LC coupled with benchtop Orbitrap high‐resolution mass spectrometry (LC‐Orbitrap‐HRMS) in full‐scan MS/dd‐MS 2 and parallel reaction monitoring (PRM). This approach enabled accurate mass measurement, chemical formula assignment, and structural elucidation via MS 2 fragmentation interpretation.
Results
The established method exhibited excellent linearity over the concentration range of 1.0–1000 nM. Resigratinib displayed low clearance in dog ( t 1/2 = 91.2 min), intermediate clearance in rat ( t 1/2 = 20.2 min), and high clearance in monkey ( t 1/2 = 6.8 min) and human ( t 1/2 = 14.0 min) systems. Ten metabolites were identified, with M3 ( bis ‐demethylation), M5 ( O ‐demethylation), and M9 ( N ‐demethylation) identified as the major metabolites. Recombinant human cytochrome P450 enzyme analysis and chemical inhibition studies indicated that CYP3A4 is the predominant enzyme responsible for resigratinib metabolism.
Conclusion
This study presents the first integrated analytical approach, combining LC–MS/MS and LC‐Orbitrap‐HRMS, for the in vitro metabolic assessment of resigratinib. The observed metabolic profiles provide an essential foundation for further toxicological and clinical investigations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
- TriApex Laboratories Co. Ltd, Nanjing, China.
- School of Pharmaceutical Science, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Pingyuan Laboratory, Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Ting Ma
Zitieren
APA
An, X., Mao, Y., Fan, A., & Ma, T. (2025). Comprehensive Metabolic Profiling of Resigratinib, a Novel FGFR Inhibitor, Using Integrated LC–MS/MS and LC‐Orbitrap‐HRMS. Rapid Communications in Mass Spectrometry. https://doi.org/10.1002/rcm.10141
Vancouver
An X, Mao Y, Fan A, Ma T. Comprehensive Metabolic Profiling of Resigratinib, a Novel FGFR Inhibitor, Using Integrated LC–MS/MS and LC‐Orbitrap‐HRMS. Rapid Communications in Mass Spectrometry. 2025. doi:10.1002/rcm.10141
BibTeX
@article{An2025,
author = {An, Xiaoxia and Mao, Yanting and Fan, Ali and Ma, Ting},
title = {Comprehensive Metabolic Profiling of Resigratinib, a Novel FGFR Inhibitor, Using Integrated LC–MS/MS and LC‐Orbitrap‐HRMS},
journal = {Rapid Communications in Mass Spectrometry},
year = {2025},
doi = {10.1002/rcm.10141}
}
EUVIMED